Platelet adhesion to arterial vascular lesions and plaques can also be inhibited by using antibodies which specifically block glycoprotein VI -dependent signal pathways.
Conventional monoclonal antibodies were developed by immunization in cooperation with the group of Meinrad Gawaz ( Medical Clinic III of the University of Tübingen) and Dr. Kremmer at Helmholtz Centre Munich, Germany. Recently, fully human recombinant antibodies have been selected from a phage library in cooperation with Morphosys AG. AdvanceCOR obtained an exclusive license from Morphosys on the clones selected from the highly diverse Ylanthia Fab antibody library. AdvanceCOR will develop and commercialize these state-of-the-art human antibodies for the treatment of myocardial infarction and stroke.
Also these antibodies including the fully human variants have already been tested in preclinical studies for efficacy and safety. The group of Prof. Wolfgang Siess at the institute for cardiovascular research at Munich investigated their efficacy by using human carotid surgery-derived plaques which were superfused with human blood.
The pros and cons of using such anti-glycoprotein VI antibodies versus glycoprotein VI fusion proteins are discussed in the editorial of Kleiman und Kolandaivelu „Expanding the Roster : Developing New Inhibitors of Intravascular Thrombosis“ in the Journal of the American College of Cardiology 2015; 65 (22): 2416 – 2419.